Downloads

https://doi.org/10.53941/ijctm.2025.100005
Subramoney, E. L., Reddy, A., & Gounden, V. Patterns of Use of Cardiac Troponins Amongst Clinicians within Public Sector Health Care Facilities in KwaZulu-Natal, South Africa. International Journal of Clinical and Translational Medicine. 2025, 1(1), 5. doi: https://doi.org/10.53941/ijctm.2025.100005
Volume 1, Issue 1, 2025
Copyright (c) 2025 by the authors.
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Original Research Articles

Patterns of Use of Cardiac Troponins Amongst Clinicians within Public Sector Health Care Facilities in KwaZulu-Natal, South Africa

Evette L. Subramoney 1,2, Ashandree Reddy 1,2 and Verena Gounden 1,2,3,*

1 Department of Chemical Pathology, National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital,
Durban 4001, South Africa

2 Department of Chemical Pathology, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa

3 Department of Clinical Biochemistry, University Hospital Galway, Newcastle Road, H91YR71 Galway, Ireland

* Correspondence: verenagounden@yahoo.com

Received: 19 January 2025; Accepted: 30 January 2025; Published: 1 March 2025

Abstract: Background: The data evaluating troponin utilisation and requesting practices in comparison to best practice guidelines is limited in developing and middle-income countries. This study aimed to assess the ordering practices of high sensitivity cardiac troponins amongst clinicians within public sector health care facilities in KwaZulu-Natal (KZN), South Africa. Methods: Requisition details and results of all cardiac troponin (cTn) requests for individuals older than 18 years analysed by the National Health Laboratory Services (NHLS) across KZN during the period 1 January 2018 to 31 December 2019 were extracted from the NHLS Central Data Warehouse. Time interval between the baseline and consecutive measurement was calculated for those who underwent serial sampling and delta troponin (percent change) determined for those samples with time interval <3 hours. Each cTn request was also assessed for concomitant requests for other cardiac biomarkers. Results: 75% of all cTn requests were analysed using a high-sensitivity assay. A serial sampling strategy (18.6%) was only observed in hospital settings with a relatively similar frequency amongst emergency departments, high care and general wards. Only 3.5% of samples represented serial samples collected within 3 h of each other. Moreover, 69% of all cTn requests had an associated request for other cardiac biomarkers, whilst 65% of CKMB requests did not have an associated cTn request. Conclusion: Awareness and adherence to clinical guidelines for the evaluation of chest pain is essential to reduce the variability of requesting practice for troponin assays.

Keywords:

myocardial infarction troponin biomarkers high-sensitivity acute coronary syndrome

References

  1. Vos, T.; Lim, S.S.; Abbafati, C.; et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020, 396, 1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9.
  2. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined —A consensus document of the Joint European Society of Cardiology/ American College of Cardiology Committee for the redefinition of myocardial infarction. Eur. Heart J. 2000, 21, 1502–1513. https://doi.org/10.1053/euhj.2000.2305.
  3. Thygesen, K.; Alpert, J.S.; White, H.D.; et al. Universal definition of myocardial infarction. Circulation 2007, 116, 2634–2653. https://doi.org/10.1161/CIRCULATIONAHA.107.187397.
  4. Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; et al. Third universal definition of myocardial infarction. Circulation 2012, 126, 2020–2035. https://doi.org/10.1161/CIRC.0b013e31826e1058.
  5. Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; et al. Fourth universal definition of myocardial infarction (2018). Circulation 2018, 138, e618–e651. https://doi.org/10.1161/CIR.0000000000000617.
  6. Collinson, P. High sensitivity troponin, analytical advantages, clinical benefits and clinical challenges—An update. Clin. Biochem. 2021, 91, 1–8 https://doi.org/10.1016/j.clinbiochem.2021.02.001.
  7. Wu, A.H.; Christenson, R.H.; Greene, D.N.; et al. Clinical Laboratory Practice Recommendations for the use of cardiac troponin in acute coronary syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force of Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. Clin. Chem. 2018, 64, 645–655. https://doi.org/10.1373/clinchem.2017.277186.
  8. Roffi, M.; Patrono, C.; Collet, J.P.; et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2016, 37, 267–315. https://doi.org/10.1093/eurheartj/ehv320.
  9. Collet, J.P.; Holger, T.; Barbato, E.; et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2021, 42, 1289–1367. https://doi.org/10.1093/eurheartj/ehaa575.
  10. Sandoval, Y.; Apple, F.S.; Mahler, S.A.; et al. High-sensitivity cardiac troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain. Circulation 2022, 146, 569–581. https://doi.org/10.1161/CIRCULATIONAHA.122.059678.
  11. Jardine, R.M.; Dalby, A.J.; Klug, E.Q.; et al. Consensus statement on the use of high sensitivity cardiac troponins. SA Heart 2012, 9, 210–215 https://doi.org/10.1161/JAHA.119.013551.
  12. Blake N, McCarrick C, Quadri T, Kleinerova J. An audit of cardiac troponin orders in Naas General Hospital. Ir J Med Sci 2016;185:S31-S127 https://doi.org/10.13140/RG.2.2.36032.99842
  13. Groarke, J.D.; Browne, L.; Margey, R.; et al. A multicentre analysis of troponin use in clinical practice. Ir. J. Med. Sci. 2013, 182, 185–190. https://doi.org/10.1007/s11845-012-0853-2.
  14. Rajappan, K.; Murphy, E.; Amber, V.; et al. Usage of troponin in the real world: A lesson for the introduction of biochemical assays. QJ Med. Int. J. Med. 2005, 98, 337–342. https://doi.org/10.1093/qjmed/hci052.
  15. Statistics South Africa. General Household Survey 2021: Summary of Findings. Statistical Release P0318. Available online: https://www.statssa.gov.za/ (accessed on 18 July 2023).
  16. Statistics South Africa. Mid-Year Population Estimates 2022: Summary of Findings. Statistical Release P0302. Available from: https://www.statssa.gov.za/ (accessed on 18 July 2023).
  17. Elshenawy, H.; Sharif, M.; Williams, K.; et al Assessment of high-sensitive troponin t monitoring in the emergency department for NSTE-ACS diagnosis: A clinical audit at manchester royal infirmary hospital. Heart 2023, 109, A75–A76.
  18. Alrusaiyes, M.F.S.; Qureshi, M.A. Appropriateness of troponin testing in emergency department at a tertiary care hospital in Saudi Arabia. Saudi Med. J. 2022, 43, 526–529. https://doi.org/10.15537/smj.2022.43.5.20210723.
  19. Thygesen, K.; Mair, J.; Giannitsis, E.; et al. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur. Heart J 2012, 33, 2252–2257. https://doi.org/10.1093/eurheartj/ehs154.
  20. Cullen, L.; Collinson, P.O.; Giannitsis, E. Point-of-care testing with high-sensitivity cardiac troponin assays: The challenges and opportunities. Emerg. Med. J. 2022, 39, 861–866. https://doi.org/10.1136/emermed-2021-211907.
  21. Collinson, P.; Suvisaari, J.; Aakre, K.M.; et al. BACKGROUND: The CARdiac MARker Guideline Uptake in Europe (CAMARGUE) program is a multi-country audit of the use of cardiac biomarkers in routine clinical practice. METHODS: An email link to a web-based questionnaire. Clin. Chem. 2021, 67, 1145.